Trump says chief of staff Susie Wiles was diagnosed with early stage breast cancerTrump says chief of staff Susie Wiles was diagnosed with early stage breast cancer
President Trump announced Monday on social media that his chief of staff, Susie Wiles, was diagnosed with early stage breast cancer. Mr. Trump also said Wiles would continue to work full time. CBS News’ Weijia Jiang has more.
WH chief of staff Susie Wiles diagnosed with early stage breast cancer, prognosis ‘excellent,’ Trump saysWH chief of staff Susie Wiles diagnosed with early stage breast cancer, prognosis ‘excellent,’ Trump says
White House chief of staff Susie Wiles has been diagnosed with early-stage breast cancer and will begin treatment immediately, President Donald Trump said Monday.Trump said Wiles has an “excellent” prognosis and plans to continue working at the White House while undergoing treatment.”Her Strength and her Commitment to continue doing the job she loves, and does so well, while undergoing treatment, tells you everything you need to know about her. Susie, as one of my closest and most important advisors, is tough and deeply committed to serving the American People,” the president wrote on his Truth Social account.”She will soon be better than ever! Melania and I are with her in every way, and we look forward to working with Susie on the many big and wonderful things that are happening for the benefit of our Country!”This is a breaking news story; check back for updates.
White House chief of staff Susie Wiles diagnosed with breast cancer, Trump saysWhite House chief of staff Susie Wiles diagnosed with breast cancer, Trump says
President Trump said White House chief of staff Susie Wiles will “continue doing the job she loves” even while undergoing treatment for early stage breast cancer.
White House chief of staff Susie Wiles diagnosed with breast cancer, Trump saysWhite House chief of staff Susie Wiles diagnosed with breast cancer, Trump says
WASHINGTON — White House chief of staff Susie Wiles was diagnosed with “early stage” breast cancer, President Donald Trump said Monday
STAT+: Structure Therapeutics reports significant weight loss from mid-stage GLP-1 pillSTAT+: Structure Therapeutics reports significant weight loss from mid-stage GLP-1 pill
Structure Therapeutics said Monday that its daily obesity pill led patients to lose about 16% of their body weight relative to placebo after 44 weeks. The results of the Phase 2 study could position the company to compete against Eli Lilly and Novo Nordisk in a high-stakes race to develop oral versions of blockbuster GLP-1 Read More
Martha Stewart’s cardiologist says a simple smoothie add-in is like ‘taking Ozempic’Martha Stewart’s cardiologist says a simple smoothie add-in is like ‘taking Ozempic’
Martha Stewart says her cardiologist compared a simple smoothie add-in to “taking Ozempic” — and now she uses it every day. The lifestyle icon revealed on a recent episode of her podcast that her cardiologist recommended beetroot powder, which she described as beneficial for cardiovascular health and weight loss. “You lose weight with it,” Stewart Read More
Dark sweet cherries may help slow aggressive breast cancer, mouse study suggestsDark sweet cherries may help slow aggressive breast cancer, mouse study suggests
From cobblers to smoothies, dark sweet cherries show up in plenty of recipes, and scientists say the crimson-colored fruit may contain compounds that could help fight an aggressive type of breast cancer.
Telehealth visits may help breast cancer patients stay on treatmentTelehealth visits may help breast cancer patients stay on treatment
Staying in touch with doctors online could help breast cancer survivors keep up their cancer treatment, according to a recent study from the University of Georgia published in the Journal of Cancer Survivorship.
Prostate cancer screening is as good as breast cancer screening, say researchersProstate cancer screening is as good as breast cancer screening, say researchers
Prostate cancer screening compares favorably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding unnecessary harms, says new research. The findings are presented at the European Association of Urology Congress (EAU26) in London. The research has also been accepted for publication in European Urology.
GLP-1 receptor agonists linked to lower mortality for patients with brain metastases, T2DMGLP-1 receptor agonists linked to lower mortality for patients with brain metastases, T2DM
For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with significantly lower all-cause mortality, according to a research letter published online March 11 in JAMA Network Open. For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 Read More